$1.03
-0.32 (-23.70%)
Open$1.20
Previous Close$1.35
Day High$1.23
Day Low$0.98
52W High$5.14
52W Low$0.82
Volume—
Avg Volume1.04M
Market Cap7.54M
P/E Ratio—
EPS$-4.32
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,733.0% upside
Current
$1.03
$1.03
Target
$29.18
$29.18
$17.82
$29.18 avg
$40.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |
| Rev Growth | +19.1% | +23.4% | +6.1% |
| Debt/Equity | 0.60 | 0.55 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |